Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724856 | 0.81 | OPRM1 (0.34) | OPRM1WDR5 | |
| SCHEMBL2037798 | 0.80 | OPRM1 (0.35) | OPRM1WDR5 | |
| SCHEMBL8104825 | 0.80 | OPRM1 (0.45) | OPRM1 | |
| SCHEMBL2300 | 0.79 | OPRM1 (0.46) | OPRM1WDR5 | |
| SCHEMBL31507302 | 0.79 | KMT2A (0.38) | OPRM1MGAT2WDR5 | |
| SCHEMBL27361622 | 0.79 | KMT2A (0.38) | OPRM1MGAT2WDR5 | |
| SCHEMBL21874062 | 0.78 | ALDH1A1 (0.47) | OPRM1TSHR | |
| SCHEMBL235086 | 0.77 | OPRM1 (0.32) | OPRM1WDR5 | |
| SCHEMBL1141221 | 0.76 | WDR5 (0.47) | OPRM1WDR5 | |
| Water SCHEMBL3901727 | 0.76 | OPRM1 (0.43) | OPRM1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | OPRM1 1988/4885TAAR1 1325/4885MGAT2 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.